A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis

A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis - A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040027

Enrollment

170

Registered

2020-04-10

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of rheumatoid arthritis who were diagnosed with the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria or the 1987 ACR criteria at Kansai Medical University Medical center. The patients of rheumatoid arthritis who were received TCZ at Kansai Medical University Medical center from April 2008 to August 2018.

Exclusion criteria

Exclusion criteria: The patients who lacked adequate medical record.

Design outcomes

Primary

Measure	Time frame
Relationship between the duration of TCZ usage and platelet volume indices before TCZ administration in the patients with rheumatoid arthritis.	—

Secondary

Measure	Time frame
DAS28-ESR, DAS28-CRP, CDAI, and SDAI in the patients of rheumatoid arthritis, observed at three, 12, 36 and 60 months after the initiation of administration of TCZ.	—

Countries

Japan

Contacts

Public ContactNobuyasu Ishii

Kansai medical university First department of international medicine

ishiinob@takii.kmu.ac.jp+81669921001

Outcome results